novel
vaccin
develop
requir
balanc
elicit
potent
immun
respons
limit
unintent
induct
hypersensit
offtarget
effect
viruslik
particl
vlp
form
subunit
vaccin
consist
selfassembl
shell
deriv
viru
capsid
protein
due
absenc
viral
genom
materi
vlp
render
nonrepl
noninfecti
enhanc
safeti
profil
comparison
subunit
vaccin
resembl
vlp
correspond
nativ
viru
provid
enhanc
immunogen
specif
vlp
capsid
protein
retain
natur
structur
conform
harbour
undamag
antigen
motif
immunolog
relev
state
inactiv
viru
vaccin
vlp
also
resembl
live
attenu
viru
without
replic
infecti
capac
due
structur
similar
utilis
similar
process
pathway
gener
vlp
consid
significantli
safer
mani
viral
deriv
vaccin
avoid
potenti
hazard
attenu
viru
revers
incomplet
inactiv
first
vlp
identifi
studi
isol
patient
infect
hepat
b
viru
hbv
bayer
et
al
due
abil
viral
capsid
protein
spontan
form
stabl
particl
mani
virus
produc
vlp
natur
byproduct
infect
cycl
engerix
glaxosmithklin
first
human
vlpbase
vaccin
licens
vaccin
hbv
sinc
number
vlp
vaccin
approv
clinic
use
includ
epax
crucel
hepat
viru
hav
recombivax
merck
hepavax
crucel
mani
other
hbv
gardasil
merck
cervarix
glaxosmithklin
human
papillomaviru
hpv
inflex
v
crucel
influenza
bolster
success
vaccin
mani
new
vlp
develop
select
exampl
summaris
tabl
addit
vlp
also
produc
variou
nonhuman
mammalian
virus
primarili
vaccin
livestock
exampl
includ
porcin
circoviru
kim
et
al
bovin
rotaviru
rodriguezlima
et
al
chicken
anaemia
viru
noteborn
et
al
koch
et
al
sar
coronaviru
liu
et
al
nipah
viru
walpita
et
al
swine
vesicular
stomat
viru
ko
et
al
spontan
polymeris
rang
viral
capsid
protein
yield
vlp
authent
geometr
symmetri
usual
icosahedr
spheric
rodlik
shape
depend
sourc
viru
vlp
gener
categoris
group
base
structur
complex
includ
singleprotein
nonenvelop
eg
vlp
deriv
calicivirus
jiang
et
al
papillomavirus
kirnbauer
et
al
parvovirus
lopez
de
turiso
et
al
multiprotein
nonenvelop
eg
vlp
deriv
infecti
bursal
diseas
viru
kibeng
et
al
polioviru
brautigam
et
al
reovirus
french
et
al
french
roy
envelop
vlp
eg
vlp
deriv
hantaan
viru
betenbaugh
et
al
hepat
c
viru
baumert
et
al
influenza
latham
galarza
retrovirus
yamshchikov
et
al
illustr
fig
singleprotein
vlp
rel
simpl
structur
multiprotein
vlp
contain
uniqu
structur
featur
sever
distinct
capsid
layer
exampl
express
variou
combin
capsid
protein
rotaviru
produc
stabl
vlp
doubl
even
tripl
capsid
layer
crawford
et
al
sabara
et
al
multiprotein
vlp
also
produc
variant
copi
protein
deriv
differ
viral
strain
mosaic
vlp
effici
confer
protect
sever
strain
viru
buonamassa
et
al
altern
mean
increas
vlp
versatil
incorpor
antigen
heterolog
sourc
chimer
vlp
contain
antigen
materi
target
sourc
support
stabl
vlp
framework
antigen
insert
peptid
vlp
capsid
protein
substructur
secondari
vlp
protein
coval
coupl
surfac
vlp
chimer
vlp
extens
rang
potenti
applic
discuss
later
chapter
envelop
vlp
consist
either
singleprotein
multiprotein
vlp
encapsul
lipid
bilay
captur
cell
membran
coexpress
haemagglutinin
ha
neuraminidas
na
matrix
protein
ion
channel
protein
influenza
viru
produc
envelop
vlp
size
morpholog
nativ
influenza
virion
includ
characterist
surfac
spike
ha
na
latham
galarza
lipid
bilay
envelop
vlp
also
support
incorpor
transmembran
anchor
protein
multipl
viral
strain
envelop
mosaic
vlp
even
heterolog
pathogen
envelop
chimer
vlp
buonaguro
et
al
halsey
et
al
visciano
et
al
vlp
structur
complex
appear
limit
intrigu
novel
construct
still
frequent
theoris
investig
vlp
natur
byproduct
produc
infect
cycl
certain
virus
bayer
et
al
characterist
benefit
effici
viru
reproduct
spontan
polymeris
capsid
protein
also
promot
format
vlp
howev
isol
vlp
produc
viral
infect
cell
effici
mean
purif
expans
rang
protein
express
system
develop
varieti
applic
effect
command
product
purif
high
qualiti
vlp
recombin
express
viral
capsid
protein
tailor
express
system
also
enabl
product
vlp
virus
routin
cultur
laboratori
common
vlp
express
system
includ
bacteria
yeast
insect
cell
line
mammalian
cell
line
plant
cellfre
cultur
express
system
benefit
pitfal
outlin
tabl
rebeaud
bachmann
vlp
produc
multipl
express
system
quaternari
structur
conform
capsid
protein
produc
vari
due
differ
posttransl
modif
phosphoryl
glycosyl
signific
effect
immunogen
vlp
modif
often
essenti
elicit
desir
immun
respons
escherichia
coli
e
coli
long
primari
laboratori
workhors
bacterium
facilit
express
purif
recombin
protein
plasmid
transform
bacteriophag
vector
deliveri
express
e
coli
often
prefer
produc
small
protein
limit
posttransl
modif
howev
larger
protein
posttransl
modif
requir
complex
express
system
eg
chines
hamster
ovari
cho
mammalian
cell
line
presenc
endotoxin
downstream
purif
also
present
signific
challeng
vaccin
develop
bacteri
express
system
vlp
uniqu
optim
express
identifi
trial
error
compar
translat
product
multipl
express
system
exampl
rabbit
haemorrhag
diseas
viru
rhdv
vlp
optim
produc
express
rhdv
capsid
protein
spodoptera
frugiperda
sf
cell
use
recombin
baculoviru
vector
young
et
al
peacey
et
al
icosahedr
vlp
diamet
around
nm
spontan
form
express
cell
vlp
contain
copi
capsid
protein
repres
rel
simpl
singleprotein
nonenvelop
vlp
vlp
structur
resembl
nativ
rhdv
virion
illustr
fig
katpal
et
al
wang
et
al
product
vlp
transgen
plant
eg
tobacco
potato
tomato
rel
new
concept
interest
applic
express
recombin
protein
plant
achiev
transgen
insert
nuclear
plastid
genom
use
plant
viral
vector
plant
cell
mammalianlik
posttransl
modif
system
plantspecif
glycosyl
immunostimulatori
effect
exampl
vlp
produc
transgen
plant
system
includ
norwalk
viru
tacket
tacket
et
al
scotti
et
al
influenza
viru
vlp
medicago
anoth
recent
develop
express
platform
cellfre
system
usual
consist
extract
e
coli
yeast
cell
develop
primarili
enabl
product
viral
capsid
protein
toxic
intermedi
protein
form
develop
vlp
contain
unnatur
amino
acid
uaa
also
achiev
use
cellfre
system
nonreplenish
natur
cellfre
system
render
method
highli
demand
scalabl
limit
influenza
vaccin
inflex
v
herzog
et
al
hepat
vaccin
epax
bovier
crucel
two
commercialis
vlp
vaccin
consist
virosom
produc
cellfre
express
system
follow
product
vlp
must
isol
express
system
purifi
suffici
qualiti
downstream
applic
vlp
usual
isol
combin
cell
lysi
remov
cellular
debri
vlp
concentr
select
purif
mammalian
insect
cell
line
secret
vlp
supernat
negat
necess
cell
lysi
vicent
et
al
resili
cell
eg
bacteria
plant
cell
may
requir
robust
mechan
manipul
ultrason
compress
abras
repeat
freezethaw
enzymat
degrad
vlp
releas
cull
mchenri
salazar
asenjo
vlp
purifi
differenti
centrifug
howev
pose
limit
scalabl
gmp
product
vaccinegrad
purifi
vlp
commerci
applic
often
involv
industrialscal
protein
purif
method
sizeexclus
ion
exchang
affin
chromatographi
column
vicent
et
al
optim
solvent
condit
must
also
identifi
maintain
vlp
stabil
solut
ph
critic
vlp
irrevers
denatur
disassembl
beyond
specif
ph
rang
exampl
rhdv
vlp
deterior
alkalin
environ
complet
vlp
disrupt
ph
fig
vlp
solubl
anoth
import
consider
vlp
may
aggreg
higher
concentr
form
insolubl
precipit
vlp
incred
versatil
vaccin
tool
addit
harbour
multipl
copi
immunolog
recognis
antigen
sourc
viru
vlp
also
use
nanoparticul
deliveri
vector
heterogen
antigen
molecul
vlp
consid
polymeris
protein
subunit
vaccin
support
modif
recombin
peptid
insert
chemic
conjug
peptid
protein
lysat
carbohydr
lipoprotein
form
chimer
vlp
vlp
support
insert
short
peptid
sequenc
specif
site
structur
capsid
protein
without
impair
vlp
format
exampl
rhdv
known
retain
abil
spontan
form
vlp
despit
recombin
insert
peptid
nterminu
cterminu
amino
acid
residu
crisci
et
al
howev
site
restrict
insert
peptid
length
residu
sequenc
nterminu
rhdv
support
insert
amino
acid
peacey
et
al
viral
protein
polyomaviru
support
insert
rang
amino
acid
eriksson
et
al
lasickien
et
al
mazeik
et
al
middelberg
et
al
inclus
secondari
capsid
protein
polyomaviru
limit
contribut
vlp
stabil
support
larg
insert
includ
truncat
protein
tegerstedt
et
al
hbv
core
antigen
hbcag
one
popular
vlp
form
viral
capsid
protein
recombin
insert
immunogen
epitop
notabl
recombin
hbc
vaccin
includ
malariavax
target
plasmodium
falciparum
p
falciparum
protozoan
respons
malaria
gregson
et
al
paninfluenza
vaccin
influenza
matrix
protein
ectodomain
univers
conserv
strain
fier
et
al
phase
clinic
trial
recombin
influenza
vaccin
acamflua
report
seroconvers
rate
amongst
particip
two
vaccin
sever
advers
sideeffect
observ
fier
et
al
recombin
nonmammalian
vlp
also
use
deliv
immunogen
peptid
deriv
mammalian
pathogen
variou
plant
virus
demonstr
promis
recombin
antigen
scaffold
includ
alfalfa
mosaic
viru
almv
vlp
contain
epitop
rabi
viru
yusibov
et
al
cowpea
mosaic
viru
cpmv
vlp
contain
epitop
bacillu
anthraci
phelp
et
al
matic
et
al
tobacco
mosaic
viru
tmv
vlp
contain
epitop
p
falciparum
turpen
et
al
potenti
applic
chimer
vlp
extend
far
beyond
incorpor
epitop
mammalian
pathogen
vlp
contain
autoantigen
natur
present
human
har
varieti
novel
role
target
angiotensin
ii
combat
hypertens
ambuhl
et
al
maurer
bachmann
target
protein
treat
alzheim
diseas
zamora
et
al
wiessner
et
al
chackerian
et
al
interrupt
cytokin
signal
pathway
spohn
et
al
link
bachmann
vlp
stimul
immun
respons
nicotin
even
investig
potenti
break
smoke
addict
maurer
et
al
cornuz
et
al
therapeut
applic
vlp
also
use
develop
novel
vaccin
cancer
exampl
recombin
insert
truncat
form
protein
polyomaviru
vlp
confer
protect
posit
mammari
carcinoma
tegerstedt
et
al
select
site
recombin
insert
chimer
vlp
provid
inher
limit
vaccin
applic
recognit
nativ
unprocess
antigen
essenti
compon
b
cell
activ
humor
immun
system
lead
antibodi
product
intern
site
insert
prevent
interact
restrict
site
insert
antigen
epitop
utilis
intracellular
process
pathway
extern
site
insert
requir
effect
b
cell
activ
depend
select
vlp
method
chimer
vlp
design
significantli
increas
complex
intern
site
insert
typic
clone
onto
intern
terminu
vlp
capsid
protein
extern
site
insert
requir
indepth
understand
capsid
protein
quaternari
structur
interact
protein
subunit
identifi
optim
site
insert
exampl
rhdv
capsid
protein
arrang
nterminu
face
intern
cterminu
face
extern
howev
quaternari
structur
conform
cterminu
fold
backward
central
protein
bulk
amino
acid
rhdv
capsid
protein
instead
identifi
potenti
extern
insert
site
exposur
immunogen
peptid
tailor
b
cell
recognit
crisci
et
al
altern
mean
avoid
limit
impos
recombin
peptid
insert
utilis
vlp
particul
scaffold
chemic
conjug
antigen
molecul
peptid
protein
lysat
carbohydr
lipoprotein
advanc
coupl
chemistri
continu
expand
list
viabl
conjug
candid
primarili
limit
effect
result
particl
size
solubl
process
conjug
use
chemic
linker
bridg
commonli
conjug
protein
acyl
amino
group
alkyl
sulfhydryl
group
activ
carboxyl
acid
residu
commonli
use
protein
coupl
chemistri
illustr
fig
smith
et
al
azidealkyn
click
chemistri
patel
swartz
complex
chackerian
et
al
also
use
vlp
conjug
heterobifunct
crosslink
two
reactiv
group
enabl
effici
protein
crosslink
howev
unfortun
sidereact
nonspecif
conjug
result
protein
aggreg
complex
solut
tumour
lysat
bioorthogon
crosslink
specif
altern
enabl
select
conjug
limit
sidereact
target
chemic
motif
absent
biolog
system
eg
phosphin
chemic
conjug
immunogen
peptid
rel
simpl
altern
recombin
insert
use
commerci
protein
crosslink
sulfosmcc
thermo
fisher
scientif
inc
rockford
il
usa
sulfosmcc
heterobifunct
crosslink
permit
stepwis
conjug
process
target
amino
group
vlp
surfac
nhsester
sulfhydryl
group
maleimid
group
cystein
residu
introduc
nterminu
target
epitop
peacey
et
al
direct
comparison
recombin
insert
chemic
conjug
peptid
lymphocyt
choreomening
viru
lcmv
chimer
rhdv
vlp
indic
recombin
form
induc
superior
vivo
cytotox
respons
li
et
al
remark
coupl
recombin
form
induc
tumourfre
surviv
respect
follow
singl
vaccin
without
adjuv
mice
graft
lewi
lung
carcinoma
tumour
express
addit
week
vaccin
boost
vlp
adjuv
increas
tumourfre
surviv
mice
vaccin
recombin
rhdv
vlp
li
et
al
conjug
larg
protein
cell
lysat
onto
surfac
vlp
enabl
induct
immun
respons
without
identif
specif
immunogen
peptid
tumour
lysat
deriv
express
melanoma
cell
line
conjug
onto
rhdv
vlp
provid
effici
lysat
deliveri
dendrit
cell
antigen
process
compart
enhanc
cell
stimul
compar
lysat
alon
win
et
al
use
tumour
lysat
vlp
vaccin
potenti
applic
personalis
anticanc
immunotherapi
although
vlp
devoid
genom
materi
sourc
viru
necessarili
alway
empti
mani
viral
structur
protein
inher
abil
bind
specif
nucleic
acid
facilit
packag
viral
genom
infect
cycl
properti
retain
vlp
appropri
encapsul
neg
charg
molecul
oligonucleotid
chemic
polym
primari
limit
intraparticul
encapsul
vlp
intern
caviti
volum
avail
posit
charg
amino
acid
zeltin
vlp
abil
encapsul
exogen
dna
explor
possibl
mean
gene
deliveri
vlp
produc
capsid
protein
human
polyomaviru
john
cunningham
jc
viru
promis
candid
abil
harbour
dna
plasmid
kbp
length
fang
et
al
deliveri
plasmid
human
epitheli
kidney
cell
subsequ
egfp
product
achiev
load
plasmid
jc
viru
vlp
osmot
shock
disrupt
vlp
structur
increas
permeabl
ou
et
al
recent
vivo
plasmid
load
express
e
coli
found
result
superior
plasmid
load
osmot
shock
vlp
reassembl
valid
jc
viru
vlp
encapsul
plasmid
chen
et
al
load
method
subsequ
use
plasmid
contain
herp
simplex
viru
thymidin
kinas
tk
suicid
gene
jc
viru
vlp
contain
found
select
target
human
colon
carcinoma
hsr
cell
graft
nude
mice
significantli
reduc
tumour
volum
follow
administr
ganciclovir
chen
et
al
chimer
vlp
also
use
encapsul
dna
plasmid
enabl
success
gene
deliveri
upon
cellular
uptak
recombin
insert
dna
bind
site
hpv
type
capsid
protein
onto
nterminu
rhdv
produc
chimer
vlp
capac
encapsul
vitro
vlp
reassembl
express
identifi
rang
cell
line
treat
contain
plasmid
el
mehdaoui
et
al
possibl
vlp
support
intern
site
insert
may
capabl
dna
plasmid
encapsul
deliveri
incorpor
appropri
dna
bind
site
vlp
even
use
induc
express
structur
capsid
protein
enhanc
immunogen
mimick
viral
replic
vivo
pichlmair
et
al
varieti
molecul
nucleic
acid
also
success
encapsul
vlp
includ
enzym
vlp
fiedler
et
al
polymeras
rotaviru
vlp
boudreaux
et
al
fluorophor
cucumb
mosaic
viru
vlp
lu
et
al
recombin
insert
heterodimer
coiledcoil
amino
acid
motif
nterminu
capsid
protein
cowpea
chlorot
mottl
viru
ccmv
produc
ccmv
vlp
capabl
encapsul
egfp
protein
minten
et
al
encapsul
exogen
protein
insid
vlp
interest
concept
multipl
potenti
therapeut
applic
immun
respons
vlp
vaccin
primarili
determin
particl
size
capsid
structur
innat
immun
activ
particl
larger
nm
requir
transport
lymph
node
peripher
antigen
present
cell
apc
vaccin
site
eg
macrophag
dendrit
cell
manolova
et
al
vlp
usual
nm
facilit
free
circul
drainag
directli
lymph
node
addit
peripher
apc
transport
lymph
node
free
vlp
internalis
resid
apc
repetit
structur
vlp
promot
effici
uptak
apc
mechan
phagocytosi
macropinocytosi
win
et
al
xiang
et
al
scheerlinck
greenwood
due
vlp
consist
nativ
viral
capsid
protein
often
contain
receptor
bind
motif
also
enabl
receptormedi
endocytosi
exampl
bind
haemagglutinin
influenza
vlp
sialylos
receptor
cell
surfac
pan
et
al
process
vlp
apc
lead
stimul
humor
cellmedi
arm
immun
system
histor
vaccin
design
target
initi
humor
immun
gener
vaccinespecif
antibodi
type
immun
respons
essenti
clearanc
extracellular
pathogen
establish
protect
intracellular
condit
viral
infect
cancer
often
requir
gener
cellmedi
immun
abil
vlp
stimul
arm
immun
system
advantag
combin
immun
respons
often
work
synergist
ensur
diseas
clearanc
initi
effect
immunolog
memori
immun
respons
vlp
summaris
fig
follow
internalis
vlp
degrad
process
exogen
antigen
process
pathway
immunogen
peptid
load
onto
mhc
class
ii
mhcii
molecul
surfac
present
process
antigen
recognis
helper
cell
result
activ
releas
immunostimulatori
cytokin
interleukin
il
essenti
b
cell
activ
essenti
induct
cellmedi
immun
success
activ
humor
immun
system
b
cell
must
also
interact
nativ
antigen
b
cell
receptor
bcr
repetit
natur
vlp
promot
crosslink
bcr
enhanc
activ
promot
memorycel
format
stimul
notabl
superior
solubl
peptid
nonrepetit
protein
jegerlehn
et
al
bachmann
jen
antibodi
produc
respons
vlp
neutralis
nativ
virion
prevent
activ
infect
memorycel
format
promot
longterm
immun
notabl
exampl
licens
vlp
vaccin
success
induc
high
titr
longlast
neutralis
antibodi
includ
hepat
b
vaccin
engerix
keat
nobl
hpv
vaccin
cervarix
gardasil
romanowski
vlp
also
crosspres
apc
primarili
dendrit
cell
facilit
load
exogen
antigen
onto
mhc
class
mhci
addit
stimul
costimulatori
molecul
eg
mhci
load
immunogen
peptid
activ
cell
initi
cellmedi
immun
respons
cytotox
lymphocyt
ctl
activ
advantag
clearanc
intracellular
condit
viral
infect
cancer
exampl
rhdv
vlp
process
receptorrecycl
pathway
crosspresent
immunogen
peptid
load
onto
mhci
phagolysosom
contain
degrad
vlp
fuse
endosom
contain
mhci
molecul
recycl
cell
surfac
win
et
al
endosom
return
cell
surfac
display
new
complex
cell
membran
illustr
fig
site
vaccin
administr
play
import
role
vlp
immunogen
mucos
membran
eg
respiratori
tract
digest
tract
urogenit
tract
common
rout
infect
gener
mucos
immun
provid
earli
protect
pathogen
intrus
number
preclin
vlp
vaccin
trial
demonstr
vlp
abil
initi
potent
mucos
immun
exampl
intranas
vaccin
cholera
toxin
b
conjug
simian
immunodefici
viru
vlp
significantli
increas
level
antibodi
detect
mucosa
compar
unconjug
cholera
toxin
b
kang
et
al
depend
protein
express
system
use
vlp
contain
exogen
immunogen
molecul
bacteri
rna
promot
apc
activ
stimul
pattern
recognit
receptor
tolllik
receptor
tlr
rebeaud
bachmann
adjuv
effect
due
activ
innat
immun
system
howev
found
success
vaccin
achiev
absenc
adjuv
molecul
li
et
al
rhdv
vlp
produc
insect
cell
cultur
stimul
innat
cell
cultur
vitro
effect
activ
cellmedi
humor
immun
system
vivo
despit
success
vlp
vaccin
alon
inclus
adjuv
still
benefici
drive
specif
immun
pathway
activ
lead
enhanc
immun
stimul
number
adjuv
use
human
includ
miner
salt
eg
aluminum
hydroxid
aluminum
phosphat
aluminum
hydroxi
phosphat
emuls
eg
microbi
deriv
monophosphoryl
lipid
cpg
rappuoli
et
al
tradit
adjuv
use
enhanc
vaccin
immunogen
stimul
humor
immun
system
induc
antibodi
product
isotypeswitch
thought
facilit
format
slowreleas
antigen
depot
modern
adjuv
design
directli
target
immun
activ
tailor
vaccin
drive
specif
immun
respons
enabl
select
stimul
cellmedi
immun
system
tlr
agonist
unmethyl
cpg
dna
induc
potent
cellmedi
respons
stimul
upregul
express
costimulatori
molecul
innat
immun
cell
found
addit
cpg
recombin
rhdv
vlp
contain
siinfekl
peptid
deriv
model
antigen
ova
vlpoti
led
enhanc
gener
siinfeklspecif
cytotox
cell
fig
scullion
associ
also
confirm
use
lewi
lung
carcinoma
model
recombin
rhdv
vlp
li
et
al
codeliveri
vaccin
adjuv
antigen
cell
physic
associ
linkag
lead
enhanc
immunogen
reduct
adjuvantrel
side
effect
virus
often
bind
molecul
facilit
entri
host
cell
rhdv
vlp
retain
abil
nativ
viru
bind
carbohydr
moieti
provid
use
mechan
modif
vaccin
enhanc
ruvoenclouet
et
al
mckee
et
al
glycolipid
adjuv
found
directli
associ
rhdv
vlp
form
composit
particl
activ
natur
killerlik
cell
lead
enhanc
innat
acquir
immun
respons
bendelac
et
al
prophylact
vaccin
recombin
rhdv
vlp
led
gener
cell
enhanc
protect
subcutan
tumour
challeng
adjuv
effect
increas
deliv
composit
particl
compar
codeliveri
unassoci
recombin
vlp
mckee
et
al
primari
requir
success
vaccin
includ
safeti
reliabl
efficaci
along
subunit
vaccin
vlp
impecc
safeti
record
vaccin
alreadi
approv
routin
use
absenc
viral
genom
render
vlp
incap
infect
replic
prevent
inadvert
revers
occur
attenu
virus
extens
purif
vlp
produc
use
protein
express
system
help
limit
contamin
substanc
might
induc
allergi
undesir
side
effect
new
vlp
extens
characteris
develop
contain
immunogen
epitop
natur
state
inactiv
viru
vaccin
particul
natur
vlp
also
provid
protect
degrad
vlp
uniform
structur
provid
consist
prepar
reliabl
vaccin
vlp
readili
process
immun
system
stimul
cytotox
humor
immun
respons
vlp
provid
protect
sourc
viru
harbour
exogen
antigen
unpreced
versatil
vaccin
design
enabl
utilis
vlp
vaccin
wide
rang
applic
includ
prophylact
viral
vaccin
therapeut
cancer
vaccin
even
gene
deliveri
vlp
vaccin
begun
unveil
true
potenti
versatil
subunit
vaccin
platform
